1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,980 | 5,250 | 12:01 | |
| 5,000 | 5,250 | 10:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.04. | KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.04. | KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING | 2 | HKEx | ||
| 28.04. | KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ... | - | HKEx | ||
| 28.04. | KEYMED BIO-B (02162): 2024 ANNUAL REPORT | - | HKEx | ||
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 27.04. | Keymed Biosciences gibt die IND-Genehmigung für CM518D1 durch die National Medical Products Administration of China zur Behandlung von Solide Tumoren bekannt | 67 | PR Newswire | CHENGDU, China, 27. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder das "Unternehmen") gab vor kurzem bekannt, dass CM518D1, ein... ► Artikel lesen | |
| 25.04. | Keymed Biosciences Announces Approval of IND for CM518D1 by the National Medical Products Administration of China for the Treatment of Solid Tumors | 275 | PR Newswire | CHENGDU, China, April 25, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed... ► Artikel lesen | |
| 07.04. | Keymed Biosciences: Daten aus Phase-III-Studie zu Stapokibart gegen saisonale allergische Rhinitis in Nature Medicine veröffentlicht | 215 | PR Newswire | CHENGDU, China, 7. April 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" oder "Unternehmen") gab heute bekannt, dass die renommierte medizinische... ► Artikel lesen | |
| 05.04. | Keymed Biosciences: The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine | 620 | PR Newswire | CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journal Nature Medicine has published... ► Artikel lesen | |
| 26.03. | Keymed Biosciences Announces Annual Results of 2024 | 114 | PR Newswire | CHENGDU, China, March 26, 2025 /PRNewswire/ -- March. 25, 2025, Keymed Biosciences Inc. (HKEX: 02162) announced its annual results of 2024, along with a corporate... ► Artikel lesen | |
| 24.03. | KEYMED BIO-B (02162): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 24.03. | KEYMED BIO-B (02162): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 24.03. | KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; AND CHANGE OF COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 12.03. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | 2 | HKEx | ||
| 10.02. | Keymed's Stapokibart approved by NMPA for seasonal allergic rhinitis | 1 | Pharmaceutical Technology | ||
| 08.02. | KeyMed Biosciences' Stapokibart Approved In China For Seasonal Allergic Rhinitis Treatment | 2 | RTTNews | ||
| 08.02. | Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis | 693 | PR Newswire | CHENGDU, China, Feb. 8, 2025 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the... ► Artikel lesen | |
| 07.02. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT NMPA APPROVED THE SNDA OF STAPOKIBART FOR THE TREATMENT OF SEASONAL ALLERGIC RHINITIS | 2 | HKEx | ||
| 21.01. | InnoCare, Keymed sell ex-China rights for bispecific to RTW-built biotech in $520M deal | 1 | FierceBiotech | ||
| 21.01. | China's KeyMed, InnoCare Grant Prolium Bio Global Rights to Cancer Drug for USD520 Million | 1 | Yicai Global | ||
| 21.01. | BRIEF: InnoCare, KeyMed in antibody licensing agree with Prolium | 1 | Bamboo Works |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
| BIONTECH | 98,95 | +1,49 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
| DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| QIAGEN | 40,315 | -0,02 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
| 89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
| ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
| KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |
Das Unternehmen KEYMED BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,760 Euro und damit -4,80 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.